von Stumm Maria, Sequeira-Gross Tatjana, Petersen Johannes, Naito Shiho, Müller Lisa, Sinning Christoph, Girdauskas Evaldas
Department of Cardiovascular Surgery, University Heart & Vascular Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Cardiology, University Heart & Vascular Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Cardiovasc Diagn Ther. 2021 Apr;11(2):503-517. doi: 10.21037/cdt-20-814.
Unicuspid aortic valve disease (UAVD) is a frequent and long-lasting challenge for adult congenital heart disease centers. UAVD patients become usually symptomatic in their twenties or thirties and require a surgical treatment plan which should respect their complete lifespan combined with an adequate quality of life. Unfortunately, all current surgical strategies of congenital aortic valve disease bear some important limitations: (I) Aortic valve replacement using bioprosthetic valves is associated with early structural degeneration and leads frequently to re-operations. (II) Mechanical valves are commonly associated with lifelong risk of severe bleeding due to oral anticoagulation. (III) Using a pulmonary autograft (i.e., Ross procedure) for aortic valve replacement is associated with excellent long-term results in non-elderly patients. However, failure of pulmonary autograft or pulmonary homograft may require re-operations. (IV) Aortic valve repair or Ozaki procedure is only performed in a few heart centers worldwide and is associated with a limited reproducibility and early patch degeneration, suture dehiscence or increased risk of endocarditis. In contrast to degenerative tricuspid aortic valve disease, UAVD remains relatively understudied and reports on UAVD treatment are rare and usually limited to retrospective single-center observations. For this review, we searched PubMed for papers in the English language by using the search words unicuspid aortic valve, congenital aortic valve, Ross procedure, Ozaki procedure, aortic valve repair, mechanical/bioprosthetic aortic replacement, homograft. We read the abstracts of relevant titles to confirm their relevance, and the full papers were then extracted. References from extracted papers were checked for additional relevant reports. This review summarizes current surgical treatment strategies for UAVD including aortic valve replacement using bioprosthetic or mechanical valves, homografts, pulmonary autografts (i.e., Ross procedure) and aortic valve repair techniques for UAV. Furthermore, Ozaki procedure will be discussed.
单叶主动脉瓣疾病(UAVD)是成人先天性心脏病中心经常面临的长期挑战。UAVD患者通常在二三十岁时出现症状,需要一个尊重其整个生命周期并具备适当生活质量的手术治疗方案。不幸的是,目前所有先天性主动脉瓣疾病的手术策略都存在一些重要局限性:(I)使用生物瓣膜进行主动脉瓣置换与早期结构退变相关,并且经常导致再次手术。(II)机械瓣膜通常与口服抗凝剂导致的终身严重出血风险相关。(III)使用肺动脉自体移植物(即Ross手术)进行主动脉瓣置换在非老年患者中具有出色的长期效果。然而,肺动脉自体移植物或肺动脉同种异体移植物失败可能需要再次手术。(IV)主动脉瓣修复或尾崎手术仅在全球少数心脏中心进行,并且与有限的可重复性以及早期补片退变、缝线裂开或心内膜炎风险增加相关。与退行性三尖瓣主动脉瓣疾病不同,UAVD的研究相对较少,关于UAVD治疗的报道很少,通常仅限于回顾性单中心观察。在本次综述中,我们在PubMed中使用关键词“单叶主动脉瓣”、“先天性主动脉瓣”、“Ross手术”、“尾崎手术”、“主动脉瓣修复”、“机械/生物人工主动脉置换”、“同种异体移植物”搜索英文论文。我们阅读相关标题的摘要以确认其相关性,然后提取全文。对提取论文的参考文献进行检查以查找其他相关报告。本综述总结了目前UAVD的手术治疗策略,包括使用生物瓣膜或机械瓣膜进行主动脉瓣置换、同种异体移植物、肺动脉自体移植物(即Ross手术)以及UAV的主动脉瓣修复技术。此外,还将讨论尾崎手术。